Ionis Pharmaceuticals

Youtube Subscribe

Open: 35.33 Close: 35.37 Change: 0.04

The best way to get information about Ionis Pharmaceuticals Company Inc: Use an AI.

Are looking for the most relevant information about Ionis Pharmaceuticals? Investor spend a lot of time searching for information to make investment decisions in Ionis Pharmaceuticals. This task is often burdensome and consumes huge amounts of free time. It also leads to mistakes due to fatigue and bounded rationality. As a solution, we programmed an artificial intelligence that reads the whole internet and the uses natural language processing and vectorizers to summarize the information. Usually, the AI reads several hundred pages and summarize it to a short document. This document presents our results. We found that the most common words in the internet about Ionis Pharmaceuticals are: Ionis, Pharmaceuticals, Monia, price, chief, executive, officer, and the most common words in the summary are: ionis, pharmaceutical, stock, back, inc, main, investor, . One of the sentences in the summary was: The revenue for the current quarter was down 65.5% compared to …

Concept Map

Semantic Network

Stock Summary

SPINRAZA for spinal muscular atrophy (SMA) in pediatric and adult patients; TEGSEDI, an antisense injection for the treatment of polyneuropathy caused by hereditary transthyretin am.

Today's Summary

Ionis Pharmaceuticals (NASDAQ: IONS) has seen its stock decline by about 11% over the last week, trading at levels of around $55 currently. The revenue for the current quarter was down 65.5% compared to the same period last year.

Today's News

Ionis Pharmaceuticals CEO Monia Monia is the chief executive officer, a member of the board of directors and a founding scientist. Monia Bennett is the executive vice president and chief scientific officer at Ionis. Bennett is one of the founding members. Ionis Pharmaceuticals (NASDAQ: IONS) has seen its stock decline by about 11% over the last week, trading at levels of around $55 currently. Ionis Pharmaceuticals first developed Qalsody, but Biogen acquired the rights to the medication in 2018. The revenue for the current quarter was down 65.5% compared to the same period last year. Royal Bank of Canada restated an “outperform” rating and set a $65.00 price target on shares of Ionis Pharmaceuticals. Barclays lowered their price objective on shares from $44.00 to $40.00 and set an ‘equal weight’ rating. Ionis Pharmaceuticals Inc stock price today is $35.37. Eplontersen paused the progression of neuropathy disease and improved neuropathy impairment and quality of life in the Phase III trial. Wall Street expects a year-over-year decline in earnings on lower revenues when Ionis Pharmaceuticals ( IONS - Free Report ) reports results for the quarter ended March 2023.

Stock Profile

"Ionis Pharmaceuticals, Inc. discovers and develops RNA-targeted therapeutics in the United States. The company offers SPINRAZA for spinal muscular atrophy (SMA) in pediatric and adult patients; TEGSEDI, an antisense injection for the treatment of polyneuropathy caused by hereditary transthyretin amyloidosis in adults; and WAYLIVRA, an antisense medicine for treatment for familial chylomicronemia syndrome (FCS) and familial partial lipodystrophy. It also develops medicines for various indications that are in phase 3 study, including Eplontersen as a monthly self-administered subcutaneous injection to treat all types of ATTR; Olezarsen for patients with FCS and severe hypertriglyceridemia (SHTG); Donidalorsen for patients with hereditary angioedema; ION363 for patients with amyotrophic lateral sclerosis; Tofersen to inhibit the production of superoxide dismutase 1; Pelacarsen for patients with established cardiovascular disease and elevated lipoprotein(a); and Bepirovirsen to inhibit the production of viral proteins associated with hepatitis B virus. In addition, the company develops Cimdelirsen to inhibit the production of growth hormone receptor; IONIS-FB-LRx to inhibit the production of complement factor B and the alternative complement pathway; and ION224 to reduce the production of diacylglycerol acyltransferase 2. It has a strategic collaboration with Biogen for the treatment of neurological disorders; and collaboration and license agreement with Metagenomi, Inc, AstraZeneca, Bayer AG, GlaxoSmithKline plc, Novartis, Roche, Swedish Orphan Biovitrum AB, and PTC Therapeutics. Ionis Pharmaceuticals, Inc. was incorporated in 1989 and is based in Carlsbad, California."

Keywords

How much time have you spent trying to decide whether investing in Ionis Pharmaceuticals? Many investors start with the dream of being free. They expect to find on the stock market an option to have time to develop their own interests and hobbies. That is, a way to escape a 9 to 5 job. However, investment is complex and investors end up spending whole days (and nights) trying to figure out which the right stock to invest is. The dream of stock investing becomes the nightmare of facing infinity amounts of information. As a solution, we programmed an artificial intelligence that reads the whole internet and the uses natural language processing and vectorizers to summarize the information. Usually, the AI reads several hundred pages and summarize it to a short document. This document presents our results. We found that the most common words in the internet about Ionis Pharmaceuticals are: Ionis, Pharmaceuticals, Monia, price, chief, executive, officer, and the most common words in the summary are: ionis, pharmaceutical, stock, back, inc, main, investor, . One of the sentences in the summary was: The revenue for the current quarter was down 65.5% compared to the same period last year.. Other searches related to this term that the AI found were: stockmarketlive, livestock, stockmarketforbeginners, thestockmarket, stockmarkettoday, stockmarkettrading, stockmarketstocks, todaystockmarket, thestockmarket, marketnews, stockmarketnews, whatisstockmarket, usstockmarket, stockmarketopen. #ionis #pharmaceutical #stock #back #inc #main #investor.

Read more →

Youtube Subscribe

---